New drug varieties of Hisilicon gradually enter the market

Statistics show that, as of yesterday, in the third quarter report of pre happy shares (excluding the listing of new shares in September), Hisense's accumulated net inflow of large single capital ranked eighth, reaching 153.8435 million yuan, with a cumulative increase of 6.44% over the same period, and the latest closing price of 22.14 yuan In terms of performance, according to the company's 2014 China Daily, the company expects a net profit of 373 million yuan to 480 million yuan from January to September 2014, a year-on-year increase of 5% to 35% (a year-on-year profit of 355 million yuan) Shanghai Securities expects the company to achieve earnings per share of 0.52 yuan and 0.66 yuan in 2014 and 2015 The median P / E ratios of Listed Companies in chemical industry in 2014 and 2015 were 37.14 times and 26.85 times respectively, and the dynamic P / E ratio of the company was the same as the industry average The growth of the company's old varieties is steady, and the gross profit rate has declined, but the new varieties gradually enter the market The company's sunflower growth plan is conducive to improving the company's academic promotion ability, the unique marketing mode is conducive to the rapid production of new varieties, improving the company's performance and gross profit level, and maintaining the company's rating of "prudent increase in holding in the next six months"